COVID-19 serological survey using micro blood sampling

Abstract During August 2020, we carried out a serological survey among students and employees at the Okinawa Institute of Science and Technology Graduate University (OIST), Japan, testing for the presence of antibodies against SARS-CoV-2, the causative agent of COVID-19. We used a FDA-authorized 2-s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Melissa M. Matthews, Tae Gyun Kim, Satoshi Shibata, Noriko Shibata, Christian Butcher, Jaekyung Hyun, Keon Young Kim, Theodore Robb, Siang Sheng Jheng, Masashi Narita, Tomoari Mori, Mary Collins, Matthias Wolf
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/89c763e1bed549368797a6b0465a12db
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:89c763e1bed549368797a6b0465a12db
record_format	dspace
spelling	oai:doaj.org-article:89c763e1bed549368797a6b0465a12db2021-12-02T14:29:09ZCOVID-19 serological survey using micro blood sampling10.1038/s41598-021-88850-z2045-2322https://doaj.org/article/89c763e1bed549368797a6b0465a12db2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88850-zhttps://doaj.org/toc/2045-2322Abstract During August 2020, we carried out a serological survey among students and employees at the Okinawa Institute of Science and Technology Graduate University (OIST), Japan, testing for the presence of antibodies against SARS-CoV-2, the causative agent of COVID-19. We used a FDA-authorized 2-step ELISA protocol in combination with at-home self-collection of blood samples using a custom low-cost finger prick-based capillary blood collection kit. Although our survey did not find any COVID-19 seropositive individuals among the OIST cohort, it reliably detected all positive control samples obtained from a local hospital and excluded all negatives controls. We found that high serum antibody titers can persist for more than 9 months post infection. Among our controls, we found strong cross-reactivity of antibodies in samples from a serum pool from two MERS patients in the anti-SARS-CoV-2-S ELISA. Here we show that a centralized ELISA in combination with patient-based capillary blood collection using as little as one drop of blood can reliably assess the seroprevalence among communities. Anonymous sample tracking and an integrated website created a stream-lined procedure. Major parts of the workflow were automated on a liquid handler, demonstrating scalability. We anticipate this concept to serve as a prototype for reliable serological testing among larger populations.Melissa M. MatthewsTae Gyun KimSatoshi ShibataNoriko ShibataChristian ButcherJaekyung HyunKeon Young KimTheodore RobbSiang Sheng JhengMasashi NaritaTomoari MoriMary CollinsMatthias WolfNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Melissa M. Matthews Tae Gyun Kim Satoshi Shibata Noriko Shibata Christian Butcher Jaekyung Hyun Keon Young Kim Theodore Robb Siang Sheng Jheng Masashi Narita Tomoari Mori Mary Collins Matthias Wolf COVID-19 serological survey using micro blood sampling
description	Abstract During August 2020, we carried out a serological survey among students and employees at the Okinawa Institute of Science and Technology Graduate University (OIST), Japan, testing for the presence of antibodies against SARS-CoV-2, the causative agent of COVID-19. We used a FDA-authorized 2-step ELISA protocol in combination with at-home self-collection of blood samples using a custom low-cost finger prick-based capillary blood collection kit. Although our survey did not find any COVID-19 seropositive individuals among the OIST cohort, it reliably detected all positive control samples obtained from a local hospital and excluded all negatives controls. We found that high serum antibody titers can persist for more than 9 months post infection. Among our controls, we found strong cross-reactivity of antibodies in samples from a serum pool from two MERS patients in the anti-SARS-CoV-2-S ELISA. Here we show that a centralized ELISA in combination with patient-based capillary blood collection using as little as one drop of blood can reliably assess the seroprevalence among communities. Anonymous sample tracking and an integrated website created a stream-lined procedure. Major parts of the workflow were automated on a liquid handler, demonstrating scalability. We anticipate this concept to serve as a prototype for reliable serological testing among larger populations.
format	article
author	Melissa M. Matthews Tae Gyun Kim Satoshi Shibata Noriko Shibata Christian Butcher Jaekyung Hyun Keon Young Kim Theodore Robb Siang Sheng Jheng Masashi Narita Tomoari Mori Mary Collins Matthias Wolf
author_facet	Melissa M. Matthews Tae Gyun Kim Satoshi Shibata Noriko Shibata Christian Butcher Jaekyung Hyun Keon Young Kim Theodore Robb Siang Sheng Jheng Masashi Narita Tomoari Mori Mary Collins Matthias Wolf
author_sort	Melissa M. Matthews
title	COVID-19 serological survey using micro blood sampling
title_short	COVID-19 serological survey using micro blood sampling
title_full	COVID-19 serological survey using micro blood sampling
title_fullStr	COVID-19 serological survey using micro blood sampling
title_full_unstemmed	COVID-19 serological survey using micro blood sampling
title_sort	covid-19 serological survey using micro blood sampling
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/89c763e1bed549368797a6b0465a12db
work_keys_str_mv	AT melissammatthews covid19serologicalsurveyusingmicrobloodsampling AT taegyunkim covid19serologicalsurveyusingmicrobloodsampling AT satoshishibata covid19serologicalsurveyusingmicrobloodsampling AT norikoshibata covid19serologicalsurveyusingmicrobloodsampling AT christianbutcher covid19serologicalsurveyusingmicrobloodsampling AT jaekyunghyun covid19serologicalsurveyusingmicrobloodsampling AT keonyoungkim covid19serologicalsurveyusingmicrobloodsampling AT theodorerobb covid19serologicalsurveyusingmicrobloodsampling AT siangshengjheng covid19serologicalsurveyusingmicrobloodsampling AT masashinarita covid19serologicalsurveyusingmicrobloodsampling AT tomoarimori covid19serologicalsurveyusingmicrobloodsampling AT marycollins covid19serologicalsurveyusingmicrobloodsampling AT matthiaswolf covid19serologicalsurveyusingmicrobloodsampling
_version_	1718391264609566720

COVID-19 serological survey using micro blood sampling

Ejemplares similares